

Global Alpha- Antitrypsin Deficiency Treatment Market Research Report 2024, Forecast to 2032

<https://marketpublishers.com/r/GD984165F440EN.html>

Date: October 2024

Pages: 190

Price: US\$ 3,200.00 (Single User License)

ID: GD984165F440EN

Abstracts

Report Overview

Alpha-1 antitrypsin deficiency (A1AD) is a hereditary disorder characterized by low levels of a protein called alpha-1 antitrypsin (A1AT) which is found in the blood. This deficiency may predispose an individual to several illnesses and most commonly manifests as chronic obstructive pulmonary disease (including bronchiectasis) and liver disease (especially cirrhosis and hepatoma), or more rarely, as a skin condition called panniculitis. A1AD is also more frequent among individuals with Wegener's granulomatosis, now called polyangiitis with granulomatosis. A deficiency of A1AT allows substances that break down proteins (so-called proteolytic enzymes) to attack various tissues of the body. The attack results in destructive changes in the lungs (emphysema) and may also affect the liver and skin. Alpha-1 antitrypsin is ordinarily released by specialized, granules within a type of white blood cells (called neutrophils or polymorphonuclear leukocytes) in response to infection or inflammation. Deficiency of alpha-1 antitrypsin results in unbalanced (i.e., relatively unopposed) rapid breakdown of proteins (protease activity), especially in the supporting elastic structures of the lungs. Over years, this destruction can lead to progressive emphysema and is accelerated by smoking, some occupational exposures, and likely by other genetic modifiers of this risk which remain incompletely understood.

The global Alpha- Antitrypsin Deficiency Treatment market size was estimated at USD 1860.60 million in 2023 and is projected to reach USD 4041.02 million by 2032, exhibiting a CAGR of 9.00% during the forecast period.

North America Alpha- Antitrypsin Deficiency Treatment market size was estimated at USD 562.51 million in 2023, at a CAGR of 7.71% during the forecast period of 2024

through 2032.

This report provides a deep insight into the global Alpha- Antitrypsin Deficiency Treatment market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.

The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Alpha- Antitrypsin Deficiency Treatment Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.

In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Alpha- Antitrypsin Deficiency Treatment market in any manner.

Global Alpha- Antitrypsin Deficiency Treatment Market: Market Segmentation Analysis

The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.

Key Company

Adverum Biotechnologies

Inc.

Alnylam Pharmaceuticals

Inc.

Applied Genetic Technologies Corporation

Arrowhead Pharmaceuticals

Inc.

Carolus Therapeutics

Inc.

Cevec Pharmaceuticals GmbH

Dicerna Pharmaceuticals

Inc.

Digna Biotech

S.L.

Editas Medicine

Inc.

Grifols

S.A.

Inhibrx

Intellia Therapeutics

Inc.

International Stem Cell Corporation

Ionis Pharmaceuticals

Inc.

Kamada Ltd.

Polyphor Ltd.

ProMetic Life Sciences Inc.

rEVO Biologics

Inc.

Sangamo BioSciences

Inc.

Market Segmentation (by Type)

CT-2009

POL-6014

ARO-AAT

ALNAAT-02

Others

Market Segmentation (by Application)

Clinic

Hospital

Others

Geographic Segmentation

North America (USA, Canada, Mexico)

Europe (Germany, UK, France, Russia, Italy, Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)

South America (Brazil, Argentina, Columbia, Rest of South America)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

Industry drivers, restraints, and opportunities covered in the study

Neutral perspective on the market performance

Recent industry trends and developments

Competitive landscape & strategies of key players

Potential & niche segments and regions exhibiting promising growth covered

Historical, current, and projected market size, in terms of value

In-depth analysis of the Alpha- Antitrypsin Deficiency Treatment Market

Overview of the regional outlook of the Alpha- Antitrypsin Deficiency Treatment Market:

Key Reasons to Buy this Report:

Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change

This enables you to anticipate market changes to remain ahead of your competitors

You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents

The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly

Provision of market value data for each segment and sub-segment

Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market

Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region

Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled

Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players

The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions

Includes in-depth analysis of the market from various perspectives through Porter's five forces analysis

Provides insight into the market through Value Chain

Market dynamics scenario, along with growth opportunities of the market in the years to come

6-month post-sales analyst support

Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Alpha- Antitrypsin Deficiency Treatment Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region from the consumer side and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 shares the main producing countries of Alpha- Antitrypsin Deficiency Treatment, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.

Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 11 provides a quantitative analysis of the market size and development potential of each region during the forecast period.

Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment during the forecast period.

Chapter 13 is the main points and conclusions of the report.

Contents

1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE

1.1 Market Definition and Statistical Scope of Alpha- Antitrypsin Deficiency Treatment

1.2 Key Market Segments

1.2.1 Alpha- Antitrypsin Deficiency Treatment Segment by Type

1.2.2 Alpha- Antitrypsin Deficiency Treatment Segment by Application

1.3 Methodology & Sources of Information

1.3.1 Research Methodology

1.3.2 Research Process

1.3.3 Market Breakdown and Data Triangulation

1.3.4 Base Year

1.3.5 Report Assumptions & Caveats

2 ALPHA- ANTITRYPSIN DEFICIENCY TREATMENT MARKET OVERVIEW

2.1 Global Market Overview

2.1.1 Global Alpha- Antitrypsin Deficiency Treatment Market Size (M USD) Estimates and Forecasts (2019-2032)

2.1.2 Global Alpha- Antitrypsin Deficiency Treatment Sales Estimates and Forecasts (2019-2032)

2.2 Market Segment Executive Summary

2.3 Global Market Size by Region

3 ALPHA- ANTITRYPSIN DEFICIENCY TREATMENT MARKET COMPETITIVE LANDSCAPE

3.1 Global Alpha- Antitrypsin Deficiency Treatment Sales by Manufacturers (2019-2024)

3.2 Global Alpha- Antitrypsin Deficiency Treatment Revenue Market Share by Manufacturers (2019-2024)

3.3 Alpha- Antitrypsin Deficiency Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.4 Global Alpha- Antitrypsin Deficiency Treatment Average Price by Manufacturers (2019-2024)

3.5 Manufacturers Alpha- Antitrypsin Deficiency Treatment Sales Sites, Area Served, Product Type

3.6 Alpha- Antitrypsin Deficiency Treatment Market Competitive Situation and Trends

3.6.1 Alpha- Antitrypsin Deficiency Treatment Market Concentration Rate

3.6.2 Global 5 and 10 Largest Alpha- Antitrypsin Deficiency Treatment Players Market Share by Revenue

3.6.3 Mergers & Acquisitions, Expansion

4 ALPHA- ANTITRYPSIN DEFICIENCY TREATMENT INDUSTRY CHAIN ANALYSIS

4.1 Alpha- Antitrypsin Deficiency Treatment Industry Chain Analysis

4.2 Market Overview of Key Raw Materials

4.3 Midstream Market Analysis

4.4 Downstream Customer Analysis

5 THE DEVELOPMENT AND DYNAMICS OF ALPHA- ANTITRYPSIN DEFICIENCY TREATMENT MARKET

5.1 Key Development Trends

5.2 Driving Factors

5.3 Market Challenges

5.4 Market Restraints

5.5 Industry News

5.5.1 New Product Developments

5.5.2 Mergers & Acquisitions

5.5.3 Expansions

5.5.4 Collaboration/Supply Contracts

5.6 Industry Policies

6 ALPHA- ANTITRYPSIN DEFICIENCY TREATMENT MARKET SEGMENTATION BY TYPE

6.1 Evaluation Matrix of Segment Market Development Potential (Type)

6.2 Global Alpha- Antitrypsin Deficiency Treatment Sales Market Share by Type (2019-2024)

6.3 Global Alpha- Antitrypsin Deficiency Treatment Market Size Market Share by Type (2019-2024)

6.4 Global Alpha- Antitrypsin Deficiency Treatment Price by Type (2019-2024)

7 ALPHA- ANTITRYPSIN DEFICIENCY TREATMENT MARKET SEGMENTATION BY APPLICATION

7.1 Evaluation Matrix of Segment Market Development Potential (Application)

7.2 Global Alpha- Antitrypsin Deficiency Treatment Market Sales by Application
(2019-2024)

7.3 Global Alpha- Antitrypsin Deficiency Treatment Market Size (M USD) by Application
(2019-2024)

7.4 Global Alpha- Antitrypsin Deficiency Treatment Sales Growth Rate by Application
(2019-2024)

8 ALPHA- ANTITRYPSIN DEFICIENCY TREATMENT MARKET CONSUMPTION BY REGION

8.1 Global Alpha- Antitrypsin Deficiency Treatment Sales by Region

8.1.1 Global Alpha- Antitrypsin Deficiency Treatment Sales by Region

8.1.2 Global Alpha- Antitrypsin Deficiency Treatment Sales Market Share by Region

8.2 North America

8.2.1 North America Alpha- Antitrypsin Deficiency Treatment Sales by Country

8.2.2 U.S.

8.2.3 Canada

8.2.4 Mexico

8.3 Europe

8.3.1 Europe Alpha- Antitrypsin Deficiency Treatment Sales by Country

8.3.2 Germany

8.3.3 France

8.3.4 U.K.

8.3.5 Italy

8.3.6 Russia

8.4 Asia Pacific

8.4.1 Asia Pacific Alpha- Antitrypsin Deficiency Treatment Sales by Region

8.4.2 China

8.4.3 Japan

8.4.4 South Korea

8.4.5 India

8.4.6 Southeast Asia

8.5 South America

8.5.1 South America Alpha- Antitrypsin Deficiency Treatment Sales by Country

8.5.2 Brazil

8.5.3 Argentina

8.5.4 Columbia

8.6 Middle East and Africa

8.6.1 Middle East and Africa Alpha- Antitrypsin Deficiency Treatment Sales by Region

8.6.2 Saudi Arabia

8.6.3 UAE

8.6.4 Egypt

8.6.5 Nigeria

8.6.6 South Africa

9 ALPHA- ANTITRYPSIN DEFICIENCY TREATMENT MARKET PRODUCTION BY REGION

9.1 Global Production of Alpha- Antitrypsin Deficiency Treatment by Region (2019-2024)

9.2 Global Alpha- Antitrypsin Deficiency Treatment Revenue Market Share by Region (2019-2024)

9.3 Global Alpha- Antitrypsin Deficiency Treatment Production, Revenue, Price and Gross Margin (2019-2024)

9.4 North America Alpha- Antitrypsin Deficiency Treatment Production

9.4.1 North America Alpha- Antitrypsin Deficiency Treatment Production Growth Rate (2019-2024)

9.4.2 North America Alpha- Antitrypsin Deficiency Treatment Production, Revenue, Price and Gross Margin (2019-2024)

9.5 Europe Alpha- Antitrypsin Deficiency Treatment Production

9.5.1 Europe Alpha- Antitrypsin Deficiency Treatment Production Growth Rate (2019-2024)

9.5.2 Europe Alpha- Antitrypsin Deficiency Treatment Production, Revenue, Price and Gross Margin (2019-2024)

9.6 Japan Alpha- Antitrypsin Deficiency Treatment Production (2019-2024)

9.6.1 Japan Alpha- Antitrypsin Deficiency Treatment Production Growth Rate (2019-2024)

9.6.2 Japan Alpha- Antitrypsin Deficiency Treatment Production, Revenue, Price and Gross Margin (2019-2024)

9.7 China Alpha- Antitrypsin Deficiency Treatment Production (2019-2024)

9.7.1 China Alpha- Antitrypsin Deficiency Treatment Production Growth Rate (2019-2024)

9.7.2 China Alpha- Antitrypsin Deficiency Treatment Production, Revenue, Price and Gross Margin (2019-2024)

10 KEY COMPANIES PROFILE

10.1 Adverum Biotechnologies

- 10.1.1 Adverum Biotechnologies Alpha- Antitrypsin Deficiency Treatment Basic Information
- 10.1.2 Adverum Biotechnologies Alpha- Antitrypsin Deficiency Treatment Product Overview
- 10.1.3 Adverum Biotechnologies Alpha- Antitrypsin Deficiency Treatment Product Market Performance
- 10.1.4 Adverum Biotechnologies Business Overview
- 10.1.5 Adverum Biotechnologies Alpha- Antitrypsin Deficiency Treatment SWOT Analysis
- 10.1.6 Adverum Biotechnologies Recent Developments
- 10.2 Inc.
 - 10.2.1 Inc. Alpha- Antitrypsin Deficiency Treatment Basic Information
 - 10.2.2 Inc. Alpha- Antitrypsin Deficiency Treatment Product Overview
 - 10.2.3 Inc. Alpha- Antitrypsin Deficiency Treatment Product Market Performance
 - 10.2.4 Inc. Business Overview
 - 10.2.5 Inc. Alpha- Antitrypsin Deficiency Treatment SWOT Analysis
 - 10.2.6 Inc. Recent Developments
- 10.3 Alnylam Pharmaceuticals
 - 10.3.1 Alnylam Pharmaceuticals Alpha- Antitrypsin Deficiency Treatment Basic Information
 - 10.3.2 Alnylam Pharmaceuticals Alpha- Antitrypsin Deficiency Treatment Product Overview
 - 10.3.3 Alnylam Pharmaceuticals Alpha- Antitrypsin Deficiency Treatment Product Market Performance
 - 10.3.4 Alnylam Pharmaceuticals Alpha- Antitrypsin Deficiency Treatment SWOT Analysis
 - 10.3.5 Alnylam Pharmaceuticals Business Overview
 - 10.3.6 Alnylam Pharmaceuticals Recent Developments
- 10.4 Inc.
 - 10.4.1 Inc. Alpha- Antitrypsin Deficiency Treatment Basic Information
 - 10.4.2 Inc. Alpha- Antitrypsin Deficiency Treatment Product Overview
 - 10.4.3 Inc. Alpha- Antitrypsin Deficiency Treatment Product Market Performance
 - 10.4.4 Inc. Business Overview
 - 10.4.5 Inc. Recent Developments
- 10.5 Applied Genetic Technologies Corporation
 - 10.5.1 Applied Genetic Technologies Corporation Alpha- Antitrypsin Deficiency Treatment Basic Information
 - 10.5.2 Applied Genetic Technologies Corporation Alpha- Antitrypsin Deficiency Treatment Product Overview

- 10.5.3 Applied Genetic Technologies Corporation Alpha- Antitrypsin Deficiency Treatment Product Market Performance
- 10.5.4 Applied Genetic Technologies Corporation Business Overview
- 10.5.5 Applied Genetic Technologies Corporation Recent Developments
- 10.6 Arrowhead Pharmaceuticals
 - 10.6.1 Arrowhead Pharmaceuticals Alpha- Antitrypsin Deficiency Treatment Basic Information
 - 10.6.2 Arrowhead Pharmaceuticals Alpha- Antitrypsin Deficiency Treatment Product Overview
 - 10.6.3 Arrowhead Pharmaceuticals Alpha- Antitrypsin Deficiency Treatment Product Market Performance
 - 10.6.4 Arrowhead Pharmaceuticals Business Overview
 - 10.6.5 Arrowhead Pharmaceuticals Recent Developments
- 10.7 Inc.
 - 10.7.1 Inc. Alpha- Antitrypsin Deficiency Treatment Basic Information
 - 10.7.2 Inc. Alpha- Antitrypsin Deficiency Treatment Product Overview
 - 10.7.3 Inc. Alpha- Antitrypsin Deficiency Treatment Product Market Performance
 - 10.7.4 Inc. Business Overview
 - 10.7.5 Inc. Recent Developments
- 10.8 Carolus Therapeutics
 - 10.8.1 Carolus Therapeutics Alpha- Antitrypsin Deficiency Treatment Basic Information
 - 10.8.2 Carolus Therapeutics Alpha- Antitrypsin Deficiency Treatment Product Overview
 - 10.8.3 Carolus Therapeutics Alpha- Antitrypsin Deficiency Treatment Product Market Performance
 - 10.8.4 Carolus Therapeutics Business Overview
 - 10.8.5 Carolus Therapeutics Recent Developments
- 10.9 Inc.
 - 10.9.1 Inc. Alpha- Antitrypsin Deficiency Treatment Basic Information
 - 10.9.2 Inc. Alpha- Antitrypsin Deficiency Treatment Product Overview
 - 10.9.3 Inc. Alpha- Antitrypsin Deficiency Treatment Product Market Performance
 - 10.9.4 Inc. Business Overview
 - 10.9.5 Inc. Recent Developments
- 10.10 Cevec Pharmaceuticals GmbH
 - 10.10.1 Cevec Pharmaceuticals GmbH Alpha- Antitrypsin Deficiency Treatment Basic Information
 - 10.10.2 Cevec Pharmaceuticals GmbH Alpha- Antitrypsin Deficiency Treatment Product Overview
 - 10.10.3 Cevec Pharmaceuticals GmbH Alpha- Antitrypsin Deficiency Treatment

Product Market Performance

10.10.4 Cevec Pharmaceuticals GmbH Business Overview

10.10.5 Cevec Pharmaceuticals GmbH Recent Developments

10.11 Dicerna Pharmaceuticals

10.11.1 Dicerna Pharmaceuticals Alpha- Antitrypsin Deficiency Treatment Basic Information

10.11.2 Dicerna Pharmaceuticals Alpha- Antitrypsin Deficiency Treatment Product Overview

10.11.3 Dicerna Pharmaceuticals Alpha- Antitrypsin Deficiency Treatment Product Market Performance

10.11.4 Dicerna Pharmaceuticals Business Overview

10.11.5 Dicerna Pharmaceuticals Recent Developments

10.12 Inc.

10.12.1 Inc. Alpha- Antitrypsin Deficiency Treatment Basic Information

10.12.2 Inc. Alpha- Antitrypsin Deficiency Treatment Product Overview

10.12.3 Inc. Alpha- Antitrypsin Deficiency Treatment Product Market Performance

10.12.4 Inc. Business Overview

10.12.5 Inc. Recent Developments

10.13 Digna Biotech

10.13.1 Digna Biotech Alpha- Antitrypsin Deficiency Treatment Basic Information

10.13.2 Digna Biotech Alpha- Antitrypsin Deficiency Treatment Product Overview

10.13.3 Digna Biotech Alpha- Antitrypsin Deficiency Treatment Product Market Performance

10.13.4 Digna Biotech Business Overview

10.13.5 Digna Biotech Recent Developments

10.14 S.L.

10.14.1 S.L. Alpha- Antitrypsin Deficiency Treatment Basic Information

10.14.2 S.L. Alpha- Antitrypsin Deficiency Treatment Product Overview

10.14.3 S.L. Alpha- Antitrypsin Deficiency Treatment Product Market Performance

10.14.4 S.L. Business Overview

10.14.5 S.L. Recent Developments

10.15 Editas Medicine

10.15.1 Editas Medicine Alpha- Antitrypsin Deficiency Treatment Basic Information

10.15.2 Editas Medicine Alpha- Antitrypsin Deficiency Treatment Product Overview

10.15.3 Editas Medicine Alpha- Antitrypsin Deficiency Treatment Product Market Performance

10.15.4 Editas Medicine Business Overview

10.15.5 Editas Medicine Recent Developments

10.16 Inc.

- 10.16.1 Inc. Alpha- Antitrypsin Deficiency Treatment Basic Information
- 10.16.2 Inc. Alpha- Antitrypsin Deficiency Treatment Product Overview
- 10.16.3 Inc. Alpha- Antitrypsin Deficiency Treatment Product Market Performance
- 10.16.4 Inc. Business Overview
- 10.16.5 Inc. Recent Developments
- 10.17 Grifols
 - 10.17.1 Grifols Alpha- Antitrypsin Deficiency Treatment Basic Information
 - 10.17.2 Grifols Alpha- Antitrypsin Deficiency Treatment Product Overview
 - 10.17.3 Grifols Alpha- Antitrypsin Deficiency Treatment Product Market Performance
 - 10.17.4 Grifols Business Overview
 - 10.17.5 Grifols Recent Developments
- 10.18 S.A.
 - 10.18.1 S.A. Alpha- Antitrypsin Deficiency Treatment Basic Information
 - 10.18.2 S.A. Alpha- Antitrypsin Deficiency Treatment Product Overview
 - 10.18.3 S.A. Alpha- Antitrypsin Deficiency Treatment Product Market Performance
 - 10.18.4 S.A. Business Overview
 - 10.18.5 S.A. Recent Developments
- 10.19 Inhibrx
 - 10.19.1 Inhibrx Alpha- Antitrypsin Deficiency Treatment Basic Information
 - 10.19.2 Inhibrx Alpha- Antitrypsin Deficiency Treatment Product Overview
 - 10.19.3 Inhibrx Alpha- Antitrypsin Deficiency Treatment Product Market Performance
 - 10.19.4 Inhibrx Business Overview
 - 10.19.5 Inhibrx Recent Developments
- 10.20 Intellia Therapeutics
 - 10.20.1 Intellia Therapeutics Alpha- Antitrypsin Deficiency Treatment Basic Information
 - 10.20.2 Intellia Therapeutics Alpha- Antitrypsin Deficiency Treatment Product Overview
 - 10.20.3 Intellia Therapeutics Alpha- Antitrypsin Deficiency Treatment Product Market Performance
 - 10.20.4 Intellia Therapeutics Business Overview
 - 10.20.5 Intellia Therapeutics Recent Developments
- 10.21 Inc.
 - 10.21.1 Inc. Alpha- Antitrypsin Deficiency Treatment Basic Information
 - 10.21.2 Inc. Alpha- Antitrypsin Deficiency Treatment Product Overview
 - 10.21.3 Inc. Alpha- Antitrypsin Deficiency Treatment Product Market Performance
 - 10.21.4 Inc. Business Overview
 - 10.21.5 Inc. Recent Developments
- 10.22 International Stem Cell Corporation
 - 10.22.1 International Stem Cell Corporation Alpha- Antitrypsin Deficiency Treatment

Basic Information

10.22.2 International Stem Cell Corporation Alpha- Antitrypsin Deficiency Treatment

Product Overview

10.22.3 International Stem Cell Corporation Alpha- Antitrypsin Deficiency Treatment

Product Market Performance

10.22.4 International Stem Cell Corporation Business Overview

10.22.5 International Stem Cell Corporation Recent Developments

10.23 Ionis Pharmaceuticals

10.23.1 Ionis Pharmaceuticals Alpha- Antitrypsin Deficiency Treatment Basic Information

10.23.2 Ionis Pharmaceuticals Alpha- Antitrypsin Deficiency Treatment Product Overview

10.23.3 Ionis Pharmaceuticals Alpha- Antitrypsin Deficiency Treatment Product Market Performance

10.23.4 Ionis Pharmaceuticals Business Overview

10.23.5 Ionis Pharmaceuticals Recent Developments

10.24 Inc.

10.24.1 Inc. Alpha- Antitrypsin Deficiency Treatment Basic Information

10.24.2 Inc. Alpha- Antitrypsin Deficiency Treatment Product Overview

10.24.3 Inc. Alpha- Antitrypsin Deficiency Treatment Product Market Performance

10.24.4 Inc. Business Overview

10.24.5 Inc. Recent Developments

10.25 Kamada Ltd.

10.25.1 Kamada Ltd. Alpha- Antitrypsin Deficiency Treatment Basic Information

10.25.2 Kamada Ltd. Alpha- Antitrypsin Deficiency Treatment Product Overview

10.25.3 Kamada Ltd. Alpha- Antitrypsin Deficiency Treatment Product Market Performance

10.25.4 Kamada Ltd. Business Overview

10.25.5 Kamada Ltd. Recent Developments

10.26 Polyphor Ltd.

10.26.1 Polyphor Ltd. Alpha- Antitrypsin Deficiency Treatment Basic Information

10.26.2 Polyphor Ltd. Alpha- Antitrypsin Deficiency Treatment Product Overview

10.26.3 Polyphor Ltd. Alpha- Antitrypsin Deficiency Treatment Product Market Performance

10.26.4 Polyphor Ltd. Business Overview

10.26.5 Polyphor Ltd. Recent Developments

10.27 ProMetic Life Sciences Inc.

10.27.1 ProMetic Life Sciences Inc. Alpha- Antitrypsin Deficiency Treatment Basic Information

10.27.2 ProMetic Life Sciences Inc. Alpha- Antitrypsin Deficiency Treatment Product Overview

10.27.3 ProMetic Life Sciences Inc. Alpha- Antitrypsin Deficiency Treatment Product Market Performance

10.27.4 ProMetic Life Sciences Inc. Business Overview

10.27.5 ProMetic Life Sciences Inc. Recent Developments

10.28 rEVO Biologics

10.28.1 rEVO Biologics Alpha- Antitrypsin Deficiency Treatment Basic Information

10.28.2 rEVO Biologics Alpha- Antitrypsin Deficiency Treatment Product Overview

10.28.3 rEVO Biologics Alpha- Antitrypsin Deficiency Treatment Product Market Performance

10.28.4 rEVO Biologics Business Overview

10.28.5 rEVO Biologics Recent Developments

10.29 Inc.

10.29.1 Inc. Alpha- Antitrypsin Deficiency Treatment Basic Information

10.29.2 Inc. Alpha- Antitrypsin Deficiency Treatment Product Overview

10.29.3 Inc. Alpha- Antitrypsin Deficiency Treatment Product Market Performance

10.29.4 Inc. Business Overview

10.29.5 Inc. Recent Developments

10.30 Sangamo BioSciences

10.30.1 Sangamo BioSciences Alpha- Antitrypsin Deficiency Treatment Basic Information

10.30.2 Sangamo BioSciences Alpha- Antitrypsin Deficiency Treatment Product Overview

10.30.3 Sangamo BioSciences Alpha- Antitrypsin Deficiency Treatment Product Market Performance

10.30.4 Sangamo BioSciences Business Overview

10.30.5 Sangamo BioSciences Recent Developments

11 ALPHA- ANTITRYPSIN DEFICIENCY TREATMENT MARKET FORECAST BY REGION

11.1 Global Alpha- Antitrypsin Deficiency Treatment Market Size Forecast

11.2 Global Alpha- Antitrypsin Deficiency Treatment Market Forecast by Region

11.2.1 North America Market Size Forecast by Country

11.2.2 Europe Alpha- Antitrypsin Deficiency Treatment Market Size Forecast by Country

11.2.3 Asia Pacific Alpha- Antitrypsin Deficiency Treatment Market Size Forecast by Region

11.2.4 South America Alpha- Antitrypsin Deficiency Treatment Market Size Forecast by Country

11.2.5 Middle East and Africa Forecasted Consumption of Alpha- Antitrypsin Deficiency Treatment by Country

12 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2032)

12.1 Global Alpha- Antitrypsin Deficiency Treatment Market Forecast by Type (2025-2032)

12.1.1 Global Forecasted Sales of Alpha- Antitrypsin Deficiency Treatment by Type (2025-2032)

12.1.2 Global Alpha- Antitrypsin Deficiency Treatment Market Size Forecast by Type (2025-2032)

12.1.3 Global Forecasted Price of Alpha- Antitrypsin Deficiency Treatment by Type (2025-2032)

12.2 Global Alpha- Antitrypsin Deficiency Treatment Market Forecast by Application (2025-2032)

12.2.1 Global Alpha- Antitrypsin Deficiency Treatment Sales (K Units) Forecast by Application

12.2.2 Global Alpha- Antitrypsin Deficiency Treatment Market Size (M USD) Forecast by Application (2025-2032)

13 CONCLUSION AND KEY FINDINGS

List Of Tables

LIST OF TABLES

Table 1. Introduction of the Type

Table 2. Introduction of the Application

Table 3. Market Size (M USD) Segment Executive Summary

Table 4. Alpha- Antitrypsin Deficiency Treatment Market Size Comparison by Region (M USD)

Table 5. Global Alpha- Antitrypsin Deficiency Treatment Sales (K Units) by Manufacturers (2019-2024)

Table 6. Global Alpha- Antitrypsin Deficiency Treatment Sales Market Share by Manufacturers (2019-2024)

Table 7. Global Alpha- Antitrypsin Deficiency Treatment Revenue (M USD) by Manufacturers (2019-2024)

Table 8. Global Alpha- Antitrypsin Deficiency Treatment Revenue Share by Manufacturers (2019-2024)

Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Alpha- Antitrypsin Deficiency Treatment as of 2022)

Table 10. Global Market Alpha- Antitrypsin Deficiency Treatment Average Price (USD/Unit) of Key Manufacturers (2019-2024)

Table 11. Manufacturers Alpha- Antitrypsin Deficiency Treatment Sales Sites and Area Served

Table 12. Manufacturers Alpha- Antitrypsin Deficiency Treatment Product Type

Table 13. Global Alpha- Antitrypsin Deficiency Treatment Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Mergers & Acquisitions, Expansion Plans

Table 15. Industry Chain Map of Alpha- Antitrypsin Deficiency Treatment

Table 16. Market Overview of Key Raw Materials

Table 17. Midstream Market Analysis

Table 18. Downstream Customer Analysis

Table 19. Key Development Trends

Table 20. Driving Factors

Table 21. Alpha- Antitrypsin Deficiency Treatment Market Challenges

Table 22. Global Alpha- Antitrypsin Deficiency Treatment Sales by Type (K Units)

Table 23. Global Alpha- Antitrypsin Deficiency Treatment Market Size by Type (M USD)

Table 24. Global Alpha- Antitrypsin Deficiency Treatment Sales (K Units) by Type (2019-2024)

Table 25. Global Alpha- Antitrypsin Deficiency Treatment Sales Market Share by Type

(2019-2024)

Table 26. Global Alpha- Antitrypsin Deficiency Treatment Market Size (M USD) by Type (2019-2024)

Table 27. Global Alpha- Antitrypsin Deficiency Treatment Market Size Share by Type (2019-2024)

Table 28. Global Alpha- Antitrypsin Deficiency Treatment Price (USD/Unit) by Type (2019-2024)

Table 29. Global Alpha- Antitrypsin Deficiency Treatment Sales (K Units) by Application

Table 30. Global Alpha- Antitrypsin Deficiency Treatment Market Size by Application

Table 31. Global Alpha- Antitrypsin Deficiency Treatment Sales by Application (2019-2024) & (K Units)

Table 32. Global Alpha- Antitrypsin Deficiency Treatment Sales Market Share by Application (2019-2024)

Table 33. Global Alpha- Antitrypsin Deficiency Treatment Sales by Application (2019-2024) & (M USD)

Table 34. Global Alpha- Antitrypsin Deficiency Treatment Market Share by Application (2019-2024)

Table 35. Global Alpha- Antitrypsin Deficiency Treatment Sales Growth Rate by Application (2019-2024)

Table 36. Global Alpha- Antitrypsin Deficiency Treatment Sales by Region (2019-2024) & (K Units)

Table 37. Global Alpha- Antitrypsin Deficiency Treatment Sales Market Share by Region (2019-2024)

Table 38. North America Alpha- Antitrypsin Deficiency Treatment Sales by Country (2019-2024) & (K Units)

Table 39. Europe Alpha- Antitrypsin Deficiency Treatment Sales by Country (2019-2024) & (K Units)

Table 40. Asia Pacific Alpha- Antitrypsin Deficiency Treatment Sales by Region (2019-2024) & (K Units)

Table 41. South America Alpha- Antitrypsin Deficiency Treatment Sales by Country (2019-2024) & (K Units)

Table 42. Middle East and Africa Alpha- Antitrypsin Deficiency Treatment Sales by Region (2019-2024) & (K Units)

Table 43. Global Alpha- Antitrypsin Deficiency Treatment Production (K Units) by Region (2019-2024)

Table 44. Global Alpha- Antitrypsin Deficiency Treatment Revenue (US\$ Million) by Region (2019-2024)

Table 45. Global Alpha- Antitrypsin Deficiency Treatment Revenue Market Share by Region (2019-2024)

Table 46. Global Alpha- Antitrypsin Deficiency Treatment Production (K Units), Revenue (US\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 47. North America Alpha- Antitrypsin Deficiency Treatment Production (K Units), Revenue (US\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 48. Europe Alpha- Antitrypsin Deficiency Treatment Production (K Units), Revenue (US\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 49. Japan Alpha- Antitrypsin Deficiency Treatment Production (K Units), Revenue (US\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 50. China Alpha- Antitrypsin Deficiency Treatment Production (K Units), Revenue (US\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 51. Adverum Biotechnologies Alpha- Antitrypsin Deficiency Treatment Basic Information

Table 52. Adverum Biotechnologies Alpha- Antitrypsin Deficiency Treatment Product Overview

Table 53. Adverum Biotechnologies Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 54. Adverum Biotechnologies Business Overview

Table 55. Adverum Biotechnologies Alpha- Antitrypsin Deficiency Treatment SWOT Analysis

Table 56. Adverum Biotechnologies Recent Developments

Table 57. Inc. Alpha- Antitrypsin Deficiency Treatment Basic Information

Table 58. Inc. Alpha- Antitrypsin Deficiency Treatment Product Overview

Table 59. Inc. Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 60. Inc. Business Overview

Table 61. Inc. Alpha- Antitrypsin Deficiency Treatment SWOT Analysis

Table 62. Inc. Recent Developments

Table 63. Alnylam Pharmaceuticals Alpha- Antitrypsin Deficiency Treatment Basic Information

Table 64. Alnylam Pharmaceuticals Alpha- Antitrypsin Deficiency Treatment Product Overview

Table 65. Alnylam Pharmaceuticals Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 66. Alnylam Pharmaceuticals Alpha- Antitrypsin Deficiency Treatment SWOT Analysis

Table 67. Alnylam Pharmaceuticals Business Overview

Table 68. Alnylam Pharmaceuticals Recent Developments

Table 69. Inc. Alpha- Antitrypsin Deficiency Treatment Basic Information

Table 70. Inc. Alpha- Antitrypsin Deficiency Treatment Product Overview

Table 71. Inc. Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 72. Inc. Business Overview

Table 73. Inc. Recent Developments

Table 74. Applied Genetic Technologies Corporation Alpha- Antitrypsin Deficiency Treatment Basic Information

Table 75. Applied Genetic Technologies Corporation Alpha- Antitrypsin Deficiency Treatment Product Overview

Table 76. Applied Genetic Technologies Corporation Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 77. Applied Genetic Technologies Corporation Business Overview

Table 78. Applied Genetic Technologies Corporation Recent Developments

Table 79. Arrowhead Pharmaceuticals Alpha- Antitrypsin Deficiency Treatment Basic Information

Table 80. Arrowhead Pharmaceuticals Alpha- Antitrypsin Deficiency Treatment Product Overview

Table 81. Arrowhead Pharmaceuticals Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 82. Arrowhead Pharmaceuticals Business Overview

Table 83. Arrowhead Pharmaceuticals Recent Developments

Table 84. Inc. Alpha- Antitrypsin Deficiency Treatment Basic Information

Table 85. Inc. Alpha- Antitrypsin Deficiency Treatment Product Overview

Table 86. Inc. Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 87. Inc. Business Overview

Table 88. Inc. Recent Developments

Table 89. Carolus Therapeutics Alpha- Antitrypsin Deficiency Treatment Basic Information

Table 90. Carolus Therapeutics Alpha- Antitrypsin Deficiency Treatment Product Overview

Table 91. Carolus Therapeutics Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 92. Carolus Therapeutics Business Overview

Table 93. Carolus Therapeutics Recent Developments

Table 94. Inc. Alpha- Antitrypsin Deficiency Treatment Basic Information

Table 95. Inc. Alpha- Antitrypsin Deficiency Treatment Product Overview

Table 96. Inc. Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 97. Inc. Business Overview

Table 98. Inc. Recent Developments

Table 99. Cevec Pharmaceuticals GmbH Alpha- Antitrypsin Deficiency Treatment Basic Information

Table 100. Cevec Pharmaceuticals GmbH Alpha- Antitrypsin Deficiency Treatment Product Overview

Table 101. Cevec Pharmaceuticals GmbH Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 102. Cevec Pharmaceuticals GmbH Business Overview

Table 103. Cevec Pharmaceuticals GmbH Recent Developments

Table 104. Dicerna Pharmaceuticals Alpha- Antitrypsin Deficiency Treatment Basic Information

Table 105. Dicerna Pharmaceuticals Alpha- Antitrypsin Deficiency Treatment Product Overview

Table 106. Dicerna Pharmaceuticals Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 107. Dicerna Pharmaceuticals Business Overview

Table 108. Dicerna Pharmaceuticals Recent Developments

Table 109. Inc. Alpha- Antitrypsin Deficiency Treatment Basic Information

Table 110. Inc. Alpha- Antitrypsin Deficiency Treatment Product Overview

Table 111. Inc. Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 112. Inc. Business Overview

Table 113. Inc. Recent Developments

Table 114. Digna Biotech Alpha- Antitrypsin Deficiency Treatment Basic Information

Table 115. Digna Biotech Alpha- Antitrypsin Deficiency Treatment Product Overview

Table 116. Digna Biotech Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 117. Digna Biotech Business Overview

Table 118. Digna Biotech Recent Developments

Table 119. S.L. Alpha- Antitrypsin Deficiency Treatment Basic Information

Table 120. S.L. Alpha- Antitrypsin Deficiency Treatment Product Overview

Table 121. S.L. Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 122. S.L. Business Overview

Table 123. S.L. Recent Developments

Table 124. Editas Medicine Alpha- Antitrypsin Deficiency Treatment Basic Information

Table 125. Editas Medicine Alpha- Antitrypsin Deficiency Treatment Product Overview

Table 126. Editas Medicine Alpha- Antitrypsin Deficiency Treatment Sales (K Units),

Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 127. Editas Medicine Business Overview

Table 128. Editas Medicine Recent Developments

Table 129. Inc. Alpha- Antitrypsin Deficiency Treatment Basic Information

Table 130. Inc. Alpha- Antitrypsin Deficiency Treatment Product Overview

Table 131. Inc. Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 132. Inc. Business Overview

Table 133. Inc. Recent Developments

Table 134. Grifols Alpha- Antitrypsin Deficiency Treatment Basic Information

Table 135. Grifols Alpha- Antitrypsin Deficiency Treatment Product Overview

Table 136. Grifols Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 137. Grifols Business Overview

Table 138. Grifols Recent Developments

Table 139. S.A. Alpha- Antitrypsin Deficiency Treatment Basic Information

Table 140. S.A. Alpha- Antitrypsin Deficiency Treatment Product Overview

Table 141. S.A. Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 142. S.A. Business Overview

Table 143. S.A. Recent Developments

Table 144. Inhibrx Alpha- Antitrypsin Deficiency Treatment Basic Information

Table 145. Inhibrx Alpha- Antitrypsin Deficiency Treatment Product Overview

Table 146. Inhibrx Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 147. Inhibrx Business Overview

Table 148. Inhibrx Recent Developments

Table 149. Intellia Therapeutics Alpha- Antitrypsin Deficiency Treatment Basic Information

Table 150. Intellia Therapeutics Alpha- Antitrypsin Deficiency Treatment Product Overview

Table 151. Intellia Therapeutics Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 152. Intellia Therapeutics Business Overview

Table 153. Intellia Therapeutics Recent Developments

Table 154. Inc. Alpha- Antitrypsin Deficiency Treatment Basic Information

Table 155. Inc. Alpha- Antitrypsin Deficiency Treatment Product Overview

Table 156. Inc. Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 157. Inc. Business Overview

Table 158. Inc. Recent Developments

Table 159. International Stem Cell Corporation Alpha- Antitrypsin Deficiency Treatment Basic Information

Table 160. International Stem Cell Corporation Alpha- Antitrypsin Deficiency Treatment Product Overview

Table 161. International Stem Cell Corporation Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 162. International Stem Cell Corporation Business Overview

Table 163. International Stem Cell Corporation Recent Developments

Table 164. Ionis Pharmaceuticals Alpha- Antitrypsin Deficiency Treatment Basic Information

Table 165. Ionis Pharmaceuticals Alpha- Antitrypsin Deficiency Treatment Product Overview

Table 166. Ionis Pharmaceuticals Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 167. Ionis Pharmaceuticals Business Overview

Table 168. Ionis Pharmaceuticals Recent Developments

Table 169. Inc. Alpha- Antitrypsin Deficiency Treatment Basic Information

Table 170. Inc. Alpha- Antitrypsin Deficiency Treatment Product Overview

Table 171. Inc. Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 172. Inc. Business Overview

Table 173. Inc. Recent Developments

Table 174. Kamada Ltd. Alpha- Antitrypsin Deficiency Treatment Basic Information

Table 175. Kamada Ltd. Alpha- Antitrypsin Deficiency Treatment Product Overview

Table 176. Kamada Ltd. Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 177. Kamada Ltd. Business Overview

Table 178. Kamada Ltd. Recent Developments

Table 179. Polyphor Ltd. Alpha- Antitrypsin Deficiency Treatment Basic Information

Table 180. Polyphor Ltd. Alpha- Antitrypsin Deficiency Treatment Product Overview

Table 181. Polyphor Ltd. Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 182. Polyphor Ltd. Business Overview

Table 183. Polyphor Ltd. Recent Developments

Table 184. ProMetic Life Sciences Inc. Alpha- Antitrypsin Deficiency Treatment Basic Information

Table 185. ProMetic Life Sciences Inc. Alpha- Antitrypsin Deficiency Treatment Product

Overview

Table 186. ProMetic Life Sciences Inc. Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 187. ProMetic Life Sciences Inc. Business Overview

Table 188. ProMetic Life Sciences Inc. Recent Developments

Table 189. rEVO Biologics Alpha- Antitrypsin Deficiency Treatment Basic Information

Table 190. rEVO Biologics Alpha- Antitrypsin Deficiency Treatment Product Overview

Table 191. rEVO Biologics Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 192. rEVO Biologics Business Overview

Table 193. rEVO Biologics Recent Developments

Table 194. Inc. Alpha- Antitrypsin Deficiency Treatment Basic Information

Table 195. Inc. Alpha- Antitrypsin Deficiency Treatment Product Overview

Table 196. Inc. Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 197. Inc. Business Overview

Table 198. Inc. Recent Developments

Table 199. Sangamo BioSciences Alpha- Antitrypsin Deficiency Treatment Basic Information

Table 200. Sangamo BioSciences Alpha- Antitrypsin Deficiency Treatment Product Overview

Table 201. Sangamo BioSciences Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 202. Sangamo BioSciences Business Overview

Table 203. Sangamo BioSciences Recent Developments

Table 204. Global Alpha- Antitrypsin Deficiency Treatment Sales Forecast by Region (2025-2032) & (K Units)

Table 205. Global Alpha- Antitrypsin Deficiency Treatment Market Size Forecast by Region (2025-2032) & (M USD)

Table 206. North America Alpha- Antitrypsin Deficiency Treatment Sales Forecast by Country (2025-2032) & (K Units)

Table 207. North America Alpha- Antitrypsin Deficiency Treatment Market Size Forecast by Country (2025-2032) & (M USD)

Table 208. Europe Alpha- Antitrypsin Deficiency Treatment Sales Forecast by Country (2025-2032) & (K Units)

Table 209. Europe Alpha- Antitrypsin Deficiency Treatment Market Size Forecast by Country (2025-2032) & (M USD)

Table 210. Asia Pacific Alpha- Antitrypsin Deficiency Treatment Sales Forecast by Region (2025-2032) & (K Units)

Table 211. Asia Pacific Alpha- Antitrypsin Deficiency Treatment Market Size Forecast by Region (2025-2032) & (M USD)

Table 212. South America Alpha- Antitrypsin Deficiency Treatment Sales Forecast by Country (2025-2032) & (K Units)

Table 213. South America Alpha- Antitrypsin Deficiency Treatment Market Size Forecast by Country (2025-2032) & (M USD)

Table 214. Middle East and Africa Alpha- Antitrypsin Deficiency Treatment Consumption Forecast by Country (2025-2032) & (Units)

Table 215. Middle East and Africa Alpha- Antitrypsin Deficiency Treatment Market Size Forecast by Country (2025-2032) & (M USD)

Table 216. Global Alpha- Antitrypsin Deficiency Treatment Sales Forecast by Type (2025-2032) & (K Units)

Table 217. Global Alpha- Antitrypsin Deficiency Treatment Market Size Forecast by Type (2025-2032) & (M USD)

Table 218. Global Alpha- Antitrypsin Deficiency Treatment Price Forecast by Type (2025-2032) & (USD/Unit)

Table 219. Global Alpha- Antitrypsin Deficiency Treatment Sales (K Units) Forecast by Application (2025-2032)

Table 220. Global Alpha- Antitrypsin Deficiency Treatment Market Size Forecast by Application (2025-2032) & (M USD)

List Of Figures

LIST OF FIGURES

Figure 1. Product Picture of Alpha- Antitrypsin Deficiency Treatment

Figure 2. Data Triangulation

Figure 3. Key Caveats

Figure 4. Global Alpha- Antitrypsin Deficiency Treatment Market Size (M USD), 2019-2032

Figure 5. Global Alpha- Antitrypsin Deficiency Treatment Market Size (M USD) (2019-2032)

Figure 6. Global Alpha- Antitrypsin Deficiency Treatment Sales (K Units) & (2019-2032)

Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)

Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)

Figure 9. Evaluation Matrix of Regional Market Development Potential

Figure 10. Alpha- Antitrypsin Deficiency Treatment Market Size by Country (M USD)

Figure 11. Alpha- Antitrypsin Deficiency Treatment Sales Share by Manufacturers in 2023

Figure 12. Global Alpha- Antitrypsin Deficiency Treatment Revenue Share by Manufacturers in 2023

Figure 13. Alpha- Antitrypsin Deficiency Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023

Figure 14. Global Market Alpha- Antitrypsin Deficiency Treatment Average Price (USD/Unit) of Key Manufacturers in 2023

Figure 15. The Global 5 and 10 Largest Players: Market Share by Alpha- Antitrypsin Deficiency Treatment Revenue in 2023

Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)

Figure 17. Global Alpha- Antitrypsin Deficiency Treatment Market Share by Type

Figure 18. Sales Market Share of Alpha- Antitrypsin Deficiency Treatment by Type (2019-2024)

Figure 19. Sales Market Share of Alpha- Antitrypsin Deficiency Treatment by Type in 2023

Figure 20. Market Size Share of Alpha- Antitrypsin Deficiency Treatment by Type (2019-2024)

Figure 21. Market Size Market Share of Alpha- Antitrypsin Deficiency Treatment by Type in 2023

Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)

Figure 23. Global Alpha- Antitrypsin Deficiency Treatment Market Share by Application

Figure 24. Global Alpha- Antitrypsin Deficiency Treatment Sales Market Share by

Application (2019-2024)

Figure 25. Global Alpha- Antitrypsin Deficiency Treatment Sales Market Share by Application in 2023

Figure 26. Global Alpha- Antitrypsin Deficiency Treatment Market Share by Application (2019-2024)

Figure 27. Global Alpha- Antitrypsin Deficiency Treatment Market Share by Application in 2023

Figure 28. Global Alpha- Antitrypsin Deficiency Treatment Sales Growth Rate by Application (2019-2024)

Figure 29. Global Alpha- Antitrypsin Deficiency Treatment Sales Market Share by Region (2019-2024)

Figure 30. North America Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (2019-2024) & (K Units)

Figure 31. North America Alpha- Antitrypsin Deficiency Treatment Sales Market Share by Country in 2023

Figure 32. U.S. Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (2019-2024) & (K Units)

Figure 33. Canada Alpha- Antitrypsin Deficiency Treatment Sales (K Units) and Growth Rate (2019-2024)

Figure 34. Mexico Alpha- Antitrypsin Deficiency Treatment Sales (Units) and Growth Rate (2019-2024)

Figure 35. Europe Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (2019-2024) & (K Units)

Figure 36. Europe Alpha- Antitrypsin Deficiency Treatment Sales Market Share by Country in 2023

Figure 37. Germany Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (2019-2024) & (K Units)

Figure 38. France Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (2019-2024) & (K Units)

Figure 39. U.K. Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (2019-2024) & (K Units)

Figure 40. Italy Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (2019-2024) & (K Units)

Figure 41. Russia Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (2019-2024) & (K Units)

Figure 42. Asia Pacific Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (K Units)

Figure 43. Asia Pacific Alpha- Antitrypsin Deficiency Treatment Sales Market Share by Region in 2023

Figure 44. China Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (2019-2024) & (K Units)

Figure 45. Japan Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (2019-2024) & (K Units)

Figure 46. South Korea Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (2019-2024) & (K Units)

Figure 47. India Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (2019-2024) & (K Units)

Figure 48. Southeast Asia Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (2019-2024) & (K Units)

Figure 49. South America Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (K Units)

Figure 50. South America Alpha- Antitrypsin Deficiency Treatment Sales Market Share by Country in 2023

Figure 51. Brazil Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (2019-2024) & (K Units)

Figure 52. Argentina Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (2019-2024) & (K Units)

Figure 53. Columbia Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (2019-2024) & (K Units)

Figure 54. Middle East and Africa Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (K Units)

Figure 55. Middle East and Africa Alpha- Antitrypsin Deficiency Treatment Sales Market Share by Region in 2023

Figure 56. Saudi Arabia Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (2019-2024) & (K Units)

Figure 57. UAE Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (2019-2024) & (K Units)

Figure 58. Egypt Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (2019-2024) & (K Units)

Figure 59. Nigeria Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (2019-2024) & (K Units)

Figure 60. South Africa Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (2019-2024) & (K Units)

Figure 61. Global Alpha- Antitrypsin Deficiency Treatment Production Market Share by Region (2019-2024)

Figure 62. North America Alpha- Antitrypsin Deficiency Treatment Production (K Units) Growth Rate (2019-2024)

Figure 63. Europe Alpha- Antitrypsin Deficiency Treatment Production (K Units) Growth

Rate (2019-2024)

Figure 64. Japan Alpha- Antitrypsin Deficiency Treatment Production (K Units) Growth Rate (2019-2024)

Figure 65. China Alpha- Antitrypsin Deficiency Treatment Production (K Units) Growth Rate (2019-2024)

Figure 66. Global Alpha- Antitrypsin Deficiency Treatment Sales Forecast by Volume (2019-2032) & (K Units)

Figure 67. Global Alpha- Antitrypsin Deficiency Treatment Market Size Forecast by Value (2019-2032) & (M USD)

Figure 68. Global Alpha- Antitrypsin Deficiency Treatment Sales Market Share Forecast by Type (2025-2032)

Figure 69. Global Alpha- Antitrypsin Deficiency Treatment Market Share Forecast by Type (2025-2032)

Figure 70. Global Alpha- Antitrypsin Deficiency Treatment Sales Forecast by Application (2025-2032)

Figure 71. Global Alpha- Antitrypsin Deficiency Treatment Market Share Forecast by Application (2025-2032)

I would like to order

Product name: Global Alpha- Antitrypsin Deficiency Treatment Market Research Report 2024, Forecast to 2032

Product link: <https://marketpublishers.com/r/GD984165F440EN.html>

Price: US\$ 3,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GD984165F440EN.html>